Free Trial
→ SpaceX IPO hides a much bigger story (From Weiss Ratings) (Ad)tc pixel Free CERO Stock Alerts

CERo Therapeutics (CERO) Competitors

CERo Therapeutics logo
$0.01 +0.00 (+25.45%)
As of 11:52 AM Eastern
Compare

CERO vs. CANF, VAXX, IMCC, ELAB, and BPTH

Should you buy CERo Therapeutics stock or one of its competitors? MarketBeat compares CERo Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CERo Therapeutics include Can-Fite BioPharma (CANF), Vaxxinity (VAXX), IM Cannabis (IMCC), PMGC (ELAB), and Bio-Path (BPTH). These companies are all part of the "pharmaceutical products" industry.

How does CERo Therapeutics compare to Can-Fite BioPharma?

CERo Therapeutics (NASDAQ:CERO) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

In the previous week, CERo Therapeutics had 1 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 1 mentions for CERo Therapeutics and 0 mentions for Can-Fite BioPharma. CERo Therapeutics' average media sentiment score of 0.00 equaled Can-Fite BioPharma'saverage media sentiment score.

Company Overall Sentiment
CERo Therapeutics Neutral
Can-Fite BioPharma Neutral

29.6% of CERo Therapeutics shares are held by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are held by institutional investors. 0.4% of CERo Therapeutics shares are held by company insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Can-Fite BioPharma has higher revenue and earnings than CERo Therapeutics. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CERo TherapeuticsN/AN/A-$8.30M-$71.01N/A
Can-Fite BioPharma$405K4.73-$7.63M-$35.80N/A

CERo Therapeutics has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

CERo Therapeutics presently has a consensus price target of $30.00, indicating a potential upside of 217,291.30%. Can-Fite BioPharma has a consensus price target of $42.50, indicating a potential upside of 1,352.99%. Given CERo Therapeutics' higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than Can-Fite BioPharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CERo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Can-Fite BioPharma
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

Company Net Margins Return on Equity Return on Assets
CERo TherapeuticsN/A N/A -209.40%
Can-Fite BioPharma N/A N/A N/A

Summary

Can-Fite BioPharma beats CERo Therapeutics on 8 of the 12 factors compared between the two stocks.

How does CERo Therapeutics compare to Vaxxinity?

Vaxxinity (NASDAQ:VAXX) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Vaxxinity is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VaxxinityN/AN/A-$56.93M-$0.45N/A
CERo TherapeuticsN/AN/A-$8.30M-$71.01N/A

In the previous week, CERo Therapeutics had 1 more articles in the media than Vaxxinity. MarketBeat recorded 1 mentions for CERo Therapeutics and 0 mentions for Vaxxinity. Vaxxinity's average media sentiment score of 0.00 equaled CERo Therapeutics'average media sentiment score.

Company Overall Sentiment
Vaxxinity Neutral
CERo Therapeutics Neutral

Company Net Margins Return on Equity Return on Assets
VaxxinityN/A N/A N/A
CERo Therapeutics N/A N/A -209.40%

82.9% of Vaxxinity shares are held by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are held by institutional investors. 64.1% of Vaxxinity shares are held by company insiders. Comparatively, 0.4% of CERo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Vaxxinity has a beta of -79.33, indicating that its stock price is 8,033% less volatile than the broader market. Comparatively, CERo Therapeutics has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market.

CERo Therapeutics has a consensus target price of $30.00, indicating a potential upside of 217,291.30%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than Vaxxinity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vaxxinity
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
CERo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Summary

CERo Therapeutics beats Vaxxinity on 6 of the 10 factors compared between the two stocks.

How does CERo Therapeutics compare to IM Cannabis?

IM Cannabis (NASDAQ:IMCC) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

CERo Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 217,291.30%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CERo Therapeutics is more favorable than IM Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IM Cannabis
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
CERo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

IM Cannabis has higher revenue and earnings than CERo Therapeutics. IM Cannabis is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IM Cannabis$50.91M0.03-$8.10M-$1.75N/A
CERo TherapeuticsN/AN/A-$8.30M-$71.01N/A

IM Cannabis has a beta of 1.99, suggesting that its stock price is 99% more volatile than the broader market. Comparatively, CERo Therapeutics has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

7.7% of IM Cannabis shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 5.9% of IM Cannabis shares are owned by insiders. Comparatively, 0.4% of CERo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, IM Cannabis had 2 more articles in the media than CERo Therapeutics. MarketBeat recorded 3 mentions for IM Cannabis and 1 mentions for CERo Therapeutics. IM Cannabis' average media sentiment score of 0.29 beat CERo Therapeutics' score of 0.00 indicating that IM Cannabis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IM Cannabis
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
CERo Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

CERo Therapeutics has a net margin of 0.00% compared to IM Cannabis' net margin of -27.65%. CERo Therapeutics' return on equity of 0.00% beat IM Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
IM Cannabis-27.65% -585.96% -39.96%
CERo Therapeutics N/A N/A -209.40%

Summary

IM Cannabis beats CERo Therapeutics on 8 of the 14 factors compared between the two stocks.

How does CERo Therapeutics compare to PMGC?

PMGC (NASDAQ:ELAB) and CERo Therapeutics (NASDAQ:CERO) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

22.2% of PMGC shares are held by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are held by institutional investors. 0.0% of PMGC shares are held by insiders. Comparatively, 0.4% of CERo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

PMGC has a beta of -0.27, suggesting that its stock price is 127% less volatile than the broader market. Comparatively, CERo Therapeutics has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

PMGC has higher revenue and earnings than CERo Therapeutics. PMGC is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PMGC$1.27M1.33-$7.75M-$168.62N/A
CERo TherapeuticsN/AN/A-$8.30M-$71.01N/A

In the previous week, PMGC had 2 more articles in the media than CERo Therapeutics. MarketBeat recorded 3 mentions for PMGC and 1 mentions for CERo Therapeutics. PMGC's average media sentiment score of 0.47 beat CERo Therapeutics' score of 0.00 indicating that PMGC is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PMGC
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
CERo Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

CERo Therapeutics' return on equity of 0.00% beat PMGC's return on equity.

Company Net Margins Return on Equity Return on Assets
PMGCN/A -117.82% -70.79%
CERo Therapeutics N/A N/A -209.40%

CERo Therapeutics has a consensus target price of $30.00, indicating a potential upside of 217,291.30%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CERo Therapeutics is more favorable than PMGC.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PMGC
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
CERo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Summary

CERo Therapeutics beats PMGC on 8 of the 13 factors compared between the two stocks.

How does CERo Therapeutics compare to Bio-Path?

Bio-Path (NASDAQ:BPTH) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

CERo Therapeutics has a consensus target price of $30.00, indicating a potential upside of 217,291.30%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CERo Therapeutics is more favorable than Bio-Path.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Path
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
CERo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

CERo Therapeutics' return on equity of 0.00% beat Bio-Path's return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-PathN/A -2,842.40% -337.48%
CERo Therapeutics N/A N/A -209.40%

Bio-Path is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-PathN/AN/A-$16.08M-$1.09N/A
CERo TherapeuticsN/AN/A-$8.30M-$71.01N/A

5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by company insiders. Comparatively, 0.4% of CERo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Bio-Path has a beta of -0.39, meaning that its share price is 139% less volatile than the broader market. Comparatively, CERo Therapeutics has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market.

In the previous week, CERo Therapeutics had 1 more articles in the media than Bio-Path. MarketBeat recorded 1 mentions for CERo Therapeutics and 0 mentions for Bio-Path. Bio-Path's average media sentiment score of 0.00 equaled CERo Therapeutics'average media sentiment score.

Company Overall Sentiment
Bio-Path Neutral
CERo Therapeutics Neutral

Summary

CERo Therapeutics beats Bio-Path on 9 of the 11 factors compared between the two stocks.

Get CERo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CERO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CERO vs. The Competition

Export
MetricCERo TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$623K$2.99B$6.50B$12.37B
Dividend YieldN/A1.76%2.67%5.66%
P/E Ratio0.0018.5824.0124.71
Price / SalesN/A468.49540.55165.59
Price / CashN/A55.8827.4837.92
Price / Book0.004.0310.556.85
Net Income-$8.30M$75.79M$3.56B$337.45M
7 Day PerformanceN/A2.68%1.54%2.70%
1 Month PerformanceN/A0.37%2.48%4.60%
1 Year PerformanceN/A24.51%26.49%32.81%

CERo Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CERO
CERo Therapeutics
0.6544 of 5 stars		$0.01
+25.5%		$30.00
+217,291.3%		-99.8%$623KN/AN/A8
CANF
Can-Fite BioPharma
1.7975 of 5 stars		$2.91
-5.5%		$42.50
+1,360.5%		-86.7%$1.91M$405KN/A8
VAXX
Vaxxinity
N/A$0.02
+7,400.0%		N/A+0.0%$1.90MN/AN/A90
IMCC
IM Cannabis
0.2742 of 5 stars		$0.25
-14.5%		N/A-90.5%$1.84M$39.17MN/A340
ELAB
PMGC
0.1765 of 5 stars		$1.41
-11.3%		N/A-99.2%$1.84M$590KN/A18

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CERO) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel